13263NVL-520-01OpenA Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)NCT05118789IndustrialBothTreatmentI/IILung; ThyroidLiu, StephenGeorgetown University Medical Center : Nicole Jimenez Lopez; Lombardi Comprehensive Cancer Center : Nicole Jimenez LopezThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC)18189Nicole Jimenez LopezNicole Jimenez Lopeznj510@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">&copy; 2026 Advarra, Inc.</a>